IDEAYA's Darovasertib Shows Promise in Neoadjuvant Uveal Melanoma Phase 2 Trial
核心洞察
IDEAYA Biosciences reports interim Phase 2 data for darovasertib in neoadjuvant uveal melanoma (搜索) (UM).
The FDA provided guidance on a registrational trial design based on a Type C meeting.
Darovasertib is a selective protein kinase C (搜索) (PKC) inhibitor targeting primary and metastatic UM.
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) has announced the upcoming release of interim Phase 2 clinical data for darovasertib in neoadjuvant uveal melanoma (搜索) (UM), along with a regulatory update from a recent FDA Type C meeting. The company plans to share these updates via a pre-market press release and investor webcast on Monday, September 23, 2024, at 8:00 a.m. ET.
Darovasertib is being developed as a potent and selective protein kinase C (搜索) (PKC) inhibitor to address both primary and metastatic UM. The investor webcast will feature a presentation reviewing the interim Phase 2 clinical data and the regulatory path forward for darovasertib in the neoadjuvant setting.
Webcast Agenda Highlights
The investor webcast presentation will cover several key areas:
- Market Introduction: Discussion of the annual incidence of UM.
- Registrational Trial Design: Outline of the registrational trial design based on guidance received from the FDA Type C meeting.
- Phase 2 Clinical Data Update: Presentation of the latest clinical efficacy and safety data from the Phase 2 trial, including baseline characteristics and adverse event (AE) profiles from both company-sponsored and investigator-sponsored trials (IST).
Participation and Access
The investor webcast and conference call will include participation from a key opinion leader, along with IDEAYA's management team, including Yujiro S. Hata, Chief Executive Officer and President, and Darrin Beaupre, M.D., Ph.D., Chief Medical Officer. Access to the webcast will be available through the Investor Relations Events section of IDEAYA's website.
About IDEAYA Biosciences
IDEAYA Biosciences is focused on precision medicine oncology, employing molecular diagnostics to identify patient populations most likely to benefit from its targeted therapies. The company's approach integrates biomarker identification and validation with drug discovery, with a focus on synthetic lethality targets.